SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing intense downward pressure driven by a combination of landmark legal rulings regarding youth addiction liabilities and investor concerns over the high capital expenditures required for the company's AI infrastructure. While bulls emphasize the stock's strong cash flow and oversold technical conditions as a long-term entry point, the community remains divided, with bears pointing to the mounting legal precedents and broader market anxiety as catalysts for a deeper pullback.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as investors focus on its role in real-world asset (RWA) tokenization, fueled by major institutional partnerships like Franklin Templeton and expanding operations on the Solana blockchain. While some in the community express frustration over price volatility and upcoming token unlocks, others remain bullish on its long-term potential to bridge traditional finance with decentralized infrastructure.

Implementing a basic decaying neuron activation model simulating the spiking behavior of a biological worm's nervous system that creates movement, and putting it on-chain  With some caveats, this is Worm - immortal digital life  The Worm will vastly outlive you or I, with the exception of global catastrophe, it is immortal digital life that inherits the resilience and decentralization of the solana network  If the underlying blockchain exists, the 'life' of The Worm will persist indefinitely

Deep Worm

The community is actively discussing a migration from WORM to NEMA, highlighting the transition toward autonomous neural simulation technology and decentralized digital organisms. Market participants are focused on the integration with protocol-level infrastructure and the launch of interactive digital pets as key drivers for renewed interest in the ecosystem.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing intense volatility as investors react to a repeating pattern of market-moving statements from the administration regarding the ongoing conflict with Iran. Community discussion is sharply divided, with traders debating whether these statements represent genuine diplomatic progress or calculated market manipulation designed to facilitate tactical shifts in the futures and options markets.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs (CLF) is facing intense market volatility and negative sentiment following a quarterly earnings miss, with community discourse heavily focused on insider selling by top executives and ongoing concerns over the company's debt levels. Despite the bearish pressure, bulls are pointing to long-term optimism regarding a potential strategic partnership with POSCO and the impact of domestic steel tariffs as key catalysts for a potential reversal.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors scrutinize the company's aggressive capital expenditures in AI and recent hiring freezes within its cloud division. The community remains deeply divided, with some traders highlighting the stock's extreme oversold status as a generational buying opportunity, while others express frustration over its persistent downward trend compared to other mega-cap tech stocks.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade is trending as investors weigh significant insider buying and strategic interest against recent volatility, with the community closely tracking potential project expansion and its role in the global energy supply landscape. Discussions are dominated by the stocks technical setup and long-term valuation potential amid ongoing geopolitical dynamics affecting global LNG demand.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is experiencing significant downward pressure as investors navigate the fallout from major shareholder divestments, including a large-scale stock sale by Fluor Corp, alongside broader sector rotation out of high-beta speculative equities. While some in the community are aggressively averaging down on the long-term thesis that SMRs are essential for AI-driven energy demand, others are wary of the stock's recent volatility and the potential for further dilution.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The DJIA is currently trending as investors closely monitor a mix of shifting Federal Reserve rate expectations and geopolitical tensions in the Middle East. Market participants are actively debating the potential for a soft landing against persistent inflation concerns, while technical analysts highlight the index's recent movement relative to key moving averages.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility as investors debate the impact of potential memory-efficiency technologies against record fundamentals and high institutional demand. While some in the community are panicking over a sharp technical correction and geopolitical uncertainties, others view the recent decline as a generational buying opportunity, emphasizing the company's strong growth in AI-driven memory and low forward valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling...

Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday...

Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.76) earnings per share for the quarter, beating analysts...

Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Status update earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - What's Next?

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization.</li><li>The company said following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs.</li><li>Seres noted that its cost-cutting measures are expected to extend its cash runway into the third quarter of 2026.</li></ul>Seres Therapeutics Inc. (MCRB) shares fell more than 21% in Thursday’s pre-market trade after the company announced that it is pausing a planned Phase 2 study, while reducing the headcount by 30% to extend its cash runway.Seres stated that it has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the U.S. Food and Drug Administration (FDA).“As we pursue earlier stage programs with the greatest opportunity, such as those targeting inflammatory bowel disease (IBD), we are exploring collaborations to provide additional capital to the company,” said Thomas DesRosier and Marella Thorell, co-CEOs of Seres.<h2 class="st-heading-2">Why Did Seres Pause The Study?</h2>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization, adding that the Phase 2 study drug substance has already been manufactured.The company said that following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs. At the same time, it will continue to seek funding for the Phase 2 study, Seres said.<h2 class="st-heading-2">Extending Cash Runway</h2>Seres noted that its cost-cutting measures, including workforce reductions, are expected to extend its cash runway into the third quarter (Q3) of 2026.The company said that this will help in supporting the continued development of its programs for inflammatory and immune-related diseases, while also giving it additional time to secure funding for the SER-155 Phase 2 study.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MCRB">Seres Therapeutics</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.One user on Stocktwits said that Seres’ announcement confirms that “there is no one interested to partner” with the company.<stembedurl>https://stocktwits.com/Kenny1207/message/644771398</stembedurl><a href="https://stocktwits.com/symbol/MCRB">MCRB stock</a> is down 51% year-to-date and 75% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/samsung-ships-world-first-commercial-hbm4-memory-module-ai-computing/cZRTlXNR4ra">Samsung Ships First Commercial HBM4 Memory Module, Nvidia’s Vera Rubin Expected To Use It: SSNLF Stock Soars 55%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Seres Therapeutics biotechnology company building, Cambridge, Massachusetts, USA

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Equity

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below Fifty Day Moving Average - Here's What Happened...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - Here's What Happened...

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50-Day Moving Average - What's Next...

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

MCRB
Seres Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MCRB News

MCRBSeres Therapeutics Inc